-
-
Current Oncology Neutrophil–lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer 2018.04.25.Curr Oncol. 2018 Apr; 25(2): e113–e119. 논문 보기PurposeThe neutrophil–lymphocyte ratio (nlr) has been reported to correlate with patient outcome in several cancers, including breast cancer. We evaluated whether the nlr can be a predictive factor for pathologic complete response (pcr) after neoadjuvant chemotherapy (nac) in patients with triple-negative breast cancer (tnbc).MethodsWe analyzed the correlation between response to nac and various factors, including the nlr, in 87 patients with tnbc who underwent nac. In addition, we analyzed the association between the nlr and recurrencefree survival (rfs) in patients with tnbc.ResultsOf the 87 patients, 25 (28.7%) achieved a pcr. A high Ki-67 index and a low nlr were significantly associated with pcr. The pcr rate was higher in patients having a high Ki-67 index (≥15%) than in those having a low Ki-67 index (35.7% vs. 0%, p = 0.002) and higher in patients having a low nlr (≤1.7) than in those having a high nlr (42.1% vs. 18.4%, p = 0.018). In multiple logistic analysis, a low nlr remained the only predictive factor for pcr (odds ratio: 4.274; p = 0.008). In the survival analysis, the rfs was significantly higher in the low nlr group than in the high nlr group (5-year rfs rate: 83.7% vs. 66.9%; log-rank p = 0.016).
Total : 35개 (page : 2/3)
-
Association analysis identifies 65 new breast cancer risk loci
-
Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high risk
-
The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier
-
The Management Strategy of Benign Solitary Intraductal Papilloma on Breast Core Biopsy
-
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
-
Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer
-
Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
-
Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice
-
Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients
-
Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience
-
Reliability of Computer-Assisted Breast Density Estimation: Comparison of Interactive Thresholding, Semiautomated, and Fully Automated Methods
-
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers
-
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
-
KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients
